Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125222 · ClinicalTrials.gov registry record · Phase 2
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT07125222: Clinical Trial Phase 2 study, sponsored by Weill Medical College of Cornell University.
NCT07125222 is a Phase 2 study that has not yet begun recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07125222, a Phase 2 study, has not yet begun recruiting, sponsored by Weill Medical College of Cornell University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Primary Outcome
The Disability Rating Scale (DRS) is a tool used to evaluate impairment, disability and handicap caused by brain injury. Scores range from 0 (No disability) to a maximum of 29 (indicating an extreme vegetative state).
Interventions
- DRUG Gocovri (extended-release amantidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-09 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
What is known before NCT07125222 opens enrollment
NCT07125222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Gocovri (extended-release amantidine) is the first listed.
NCT07125222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07125222 about?
NCT07125222 is a clinical study titled "Use of Gocovri to Improve Disability Due to Radiation Encephalopathy". A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
What is the current status of trial NCT07125222?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-09. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07125222?
The interventions under investigation include: Gocovri (extended-release amantidine) (DRUG).
Who is sponsoring clinical trial NCT07125222?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07125222's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia